RESUMO
In this prospective study the presence of clinically detectable hypersensitivity reactions following intravenous administration of 5% human serum albumin (HSA) was evaluated in 73 critically ill dogs both during the infusion, within the initial 24 hours afterwards, and at 7, 14, 21 and 28 days. A dose range of 2.0-20.56 mL/kg of 5% HSA was administered at a standard rate of 2.0 ml/kg/h IV in the critically ill dogs. No clinical signs consistent with types I and III hypersensitivity reactions were noted at days 0, 7, 14, 21 and 28. Previous studies have recorded types I and III hypersensitivity reactions following HSA infusion with variable concentrations, rates and volumes infused. This study demonstrated the safe administration of 5% HSA at a standard rate of administration with no reactions.